Business
BELLUS Health ends NC-503 diabetes development program following results
BELLUS Health ends NC-503 diabetes development program following results
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n May 4, 2010 (Canada NewsWire Group) -- LAVAL, QC, May 4 /CNW Telbec/ - BELLUS Health (TSX: BLU) announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.\n"While we are disappointed that the NC-503 indication for Type 2 Diabetes did not prove to be effective, our decision today enables us to preserve shareholder value and conserve our financial and human resources for projects that we believe have high potential for success," said Roberto Bellini, President and Chief Executive Officer of BELLUS Health.\n\nAbout NC-503 (eprodisate disodium)\n\nNC-503 (eprodisate disodium, KIACTA(TM)) is a small molecule that is currently being developed for the treatment of AA amyloidosis, a rare disease related to the systemic extracellular deposition of insoluble fibrillar proteins (amyloid) mostly on the kidneys. While eprodisate has been shown to have protective effects on renal function in AA amyloidosis patients in a clinical Phase III study, pre-clinical rodent model data had also suggested that eprodisate had glucose lowering activity and could improve features of metabolic syndrome.\n\nAbout BELLUS Health\n\nBELLUS Health is a global health company focused on the research and development of products to provide innovative health solutions to address critical unmet medical needs. For further information, please visit www.bellushealth.com.\n\nForward Looking Statements\n\nCertain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitiv...